TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2952151

Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 641

Group type: COMPARATOR
Intervention: Ionic monomers
Number of subjects: 641
Study: 31648564

Group type: EXPERIMENTAL
Intervention: Prednisone (5 mg/kg) for 4 weeks
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Prednisolone (5 mg/kg) for 4 weeks
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oral administration of prednisone (20 mg for 5 days)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Increasing concentrations (0-200 ng/mL) of prednisone or prednisolone
Number of subjects: 9

Group type: COMPARATOR
Intervention: GC-receptor antagonist (RU486)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Glucocorticoids in fibroblasts
Number of subjects: 9
Study: 29514574

Group type: EXPERIMENTAL
Intervention: Ethical empowerment program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 27530961

Group type: EXPERIMENTAL
Intervention: BEAT Cancer
Number of subjects: 222
Study: 26036965

Group type: EXPERIMENTAL
Intervention: Girls Active intervention
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Usual practice (Control)
Number of subjects: 1600
Study: 23520150

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH; tinzaparin)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Usual care (tinzaparin plus warfarin for ≥12 weeks at home)
Number of subjects: 480
Study: 21538451

Group type: EXPERIMENTAL
Intervention: Generic drug
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard drug
Number of subjects: 0
Study: 19357918

Group type: EXPERIMENTAL
Intervention: 0.5% Marcaine
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 73
Study: 17823445

Group type: EXPERIMENTAL
Intervention: Soybean isoflavones with inulin (3.66 g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Soybean isoflavones without inulin
Number of subjects: 12
Study: 15282384

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP; 250 microg twice daily) for 2 weeks
Number of subjects: 10
Study: 11606172

Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 9602688

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg for 30 to 40 days (mean 35)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Azithromycin 1000 mg for 21 to 50 days (mean 37)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Azithromycin 1500 mg for 20 days
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Low dose maintenance treatment with azithromycin for 30 to 360 days (mean 129)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Short term initial course of azithromycin (various doses)
Number of subjects: 13
Study: 7516576

Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 2711711

Group type: EXPERIMENTAL
Intervention: Non‐medicamentous therapy (CNT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Medicamentous therapy
Number of subjects: 73
Study: 14253279

Group type: EXPERIMENTAL
Intervention: Hydroxyurea at 12.5, 25.0, 37.5, and 50.0 mg/kg
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Hydroxyurea administered parenterally
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Hydroxyurea at 25.0, 37.5, and 50.0 mg/kg
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Hydroxyurea calculated by surface area
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Hydroxyurea at 12.5 mg/kg (low dose)
Number of subjects: 110
Study: 344159

Group type: EXPERIMENTAL
Intervention: Glucagon (2 X 5 mg protamine-zinc glucagon intramuscularly per day)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Glucagon and Placebo (total group of 69 patients)
Number of subjects: 69
Study: 31924562

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 9901

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9901
Study: 31348727

Group type: EXPERIMENTAL
Intervention: Wobble board exercises combined with conventional physiotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 30
Study: 29949284

Group type: EXPERIMENTAL
Intervention: Pertubation treatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Stable group (control)
Number of subjects: 42
Study: 25492501

Group type: EXPERIMENTAL
Intervention: Once-only colonoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biennial fecal immunochemical testing
Number of subjects: 0
Study: 23344921

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 20833822

Group type: EXPERIMENTAL
Intervention: Sirolimus (SIR)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 181
Study: 19967596

Group type: EXPERIMENTAL
Intervention: 6.4% carbohydrate‐electrolyte solution
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 17
Study: 17218326

Group type: EXPERIMENTAL
Intervention: Health assessment programme
Number of subjects: 453
Study: 15126989

Group type: EXPERIMENTAL
Intervention: High-dose rhASB (1.0 mg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low-dose rhASB (0.2 mg/kg)
Number of subjects: 6
Study: 12641012

Group type: EXPERIMENTAL
Intervention: Beta- and gamma-based vascular brachytherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dose around 20 Gy of brachytherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled dose escalation of brachytherapy
Number of subjects: 0
Study: 9817690

Group type: EXPERIMENTAL
Intervention: Methylprednisolone treatment (n = 11)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 29
Study: 7656830

Group type: EXPERIMENTAL
Intervention: ondansetron
Number of subjects: 167

Group type: COMPARATOR
Intervention: metoclopramide
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: ondansetron (Qi Lu)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: ondansetron (Qi Lu) and Zofran (Glaxo)
Number of subjects: 167
Study: 2570971

Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol patches (2 x 100 micrograms) with norethisterone 5 mg from day 19-26 of the cycle
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo patches with norethisterone 5 mg from day 19-26 of the cycle
Number of subjects: 40
Study: 1233519

Group type: EXPERIMENTAL
Intervention: Oral diazepam, 30 mgs. daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desmethyl-diazepam products
Number of subjects: 0
Study: 30157115

Group type: EXPERIMENTAL
Intervention: Oral iron supplementation
Number of subjects: 1165

Group type: COMPARATOR
Intervention: No oral iron supplementation (Control)
Number of subjects: 1165

Group type: EXPERIMENTAL
Intervention: Oral iron supplementation in hypertensive participants
Number of subjects: 1165

Group type: EXPERIMENTAL
Intervention: Oral iron supplementation in hypertensive participants without anemia
Number of subjects: 1165
Study: 28501522

Group type: EXPERIMENTAL
Intervention: Flosequinan (75 or 100 mg/day)
Number of subjects: 2354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2354

Group type: EXPERIMENTAL
Intervention: Flosequinan
Number of subjects: 2354

Group type: EXPERIMENTAL
Intervention: Flosequinan withdrawal
Number of subjects: 2354
Study: 25385685

Group type: EXPERIMENTAL
Intervention: Comprehensive Transition Program (CTP)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard Clinical Practice (SCP)
Number of subjects: 26
Study: 24621800

Group type: EXPERIMENTAL
Intervention: NT-proBNP-guided therapy
Number of subjects: 467

Group type: COMPARATOR
Intervention: Symptom-guided therapy
Number of subjects: 467
Study: 21534496

Group type: EXPERIMENTAL
Intervention: Wavefront-optimized ablation (group I)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Topography-guided ablation (group II)
Number of subjects: 84
Study: 19225269

Group type: EXPERIMENTAL
Intervention: Prolonged guided computer use with internet connection for 12 months
Number of subjects: 191

Group type: COMPARATOR
Intervention: Training/No intervention
Number of subjects: 191

Group type: COMPARATOR
Intervention: No training/No intervention
Number of subjects: 191

Group type: COMPARATOR
Intervention: No interest in computer use
Number of subjects: 191
Study: 16860018

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: Abciximab (with/without)
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: Thrombolysis In Myocardial Infarction grade 3 flow at baseline
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: Ejection fraction
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: Ischemic target vessel revascularization
Number of subjects: 2082
Study: 14500934

Group type: EXPERIMENTAL
Intervention: Elevated weighted average MAP
Number of subjects: 1455

Group type: EXPERIMENTAL
Intervention: 30% increase from baseline MAP
Number of subjects: 1455
Study: 11578994

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 9872520

Group type: EXPERIMENTAL
Intervention: OAC (500 mg t.i.d. amoxicillin, 200 mg t.i.d. clarithromycin, 20 mg q.d. omeprazole)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Ox2AC (500 mg t.i.d. amoxicillin, 200 mg t.i.d. clarithromycin, 20 mg b.i.d. omeprazole)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: OACS (500 mg t.i.d. amoxicillin, 200 mg t.i.d. clarithromycin, 20 mg q.d. omeprazole, 100 mg t.i.d. sofalcone)
Number of subjects: 109
Study: 7913155

Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate (50 micrograms twice daily) plus BDP
Number of subjects: 429

Group type: COMPARATOR
Intervention: Higher-dose BDP (500 micrograms twice daily)
Number of subjects: 429
Study: 2915235

Group type: EXPERIMENTAL
Intervention: Intensive therapy (repetitive pulse vincristine, dactinomycin, and cyclophosphamide (VAC) for 2 years)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard VAC therapy for 2 years or VA for 1 year (Control)
Number of subjects: 74
Study: 1104047

Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Atenolol 400 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg/day with bendrofluazide 5 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bendrofluazide 5 mg/day
Number of subjects: 24
Study: 31715553

Group type: EXPERIMENTAL
Intervention: Thin-ideal images
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control images (scenery)
Number of subjects: 126
Study: 30035357

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided dorsal penile nerve block
Number of subjects: 310

Group type: COMPARATOR
Intervention: Landmark dorsal penile nerve block
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 310
Study: 26172217

Group type: EXPERIMENTAL
Intervention: Knowledge of PrEP
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Support for PrEP availability outside a clinical trial
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Barriers to supporting PrEP availability
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Patient inquiries about PrEP
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Patient inquiries in non-PROUD clinics
Number of subjects: 328
Study: 24912464

Group type: EXPERIMENTAL
Intervention: Escape modeling group (parent models premature termination of hyperventilation exercise)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No escape modeling group (parent models completing hyperventilation exercise)
Number of subjects: 50
Study: 21987394

Group type: EXPERIMENTAL
Intervention: Gantenerumab 60 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Gantenerumab 200 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Gantenerumab (ex vivo)
Number of subjects: 16
Study: 20367671

Group type: EXPERIMENTAL
Intervention: Hydroglycolic extract of Piptadenia colubrina (HEPC) in a gel-cream formulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 18068618

Group type: EXPERIMENTAL
Intervention: Plasma N-BNP
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Plasma MMP-9
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Plasma MMP-2
Number of subjects: 52
Study: 15909264

Group type: EXPERIMENTAL
Intervention: Antifungal therapy (mold-active antifungal drugs)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Index cutoff value of 1.5
Number of subjects: 315

Group type: COMPARATOR
Intervention: Index cutoff value of 0.5
Number of subjects: 315

Group type: COMPARATOR
Intervention: Per-test calculations with index cutoff value of 1.5
Number of subjects: 315

Group type: COMPARATOR
Intervention: Per-test calculations with index cutoff value of 0.5
Number of subjects: 315
Study: 12492201

Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg b.i.d.
Number of subjects: 801

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 801
Study: 9951478

Group type: EXPERIMENTAL
Intervention: Indocyanine green angiography
Number of subjects: 19
Study: 7811172

Group type: EXPERIMENTAL
Intervention: Energy-storing foot (Proteor)
Number of subjects: 24

Group type: COMPARATOR
Intervention: SACH foot
Number of subjects: 24
Study: 2108645

Group type: EXPERIMENTAL
Intervention: Anistreplase (Eminase)
Number of subjects: 0
Study: 108715

Group type: EXPERIMENTAL
Intervention: 0.25 mg haloperidol intravenous (IV)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 0.50 mg haloperidol intravenous (IV)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 0.25 mg haloperidol intramuscular (IM)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 0.50 mg haloperidol intramuscular (IM)
Number of subjects: 7
Study: 30745518

Group type: EXPERIMENTAL
Intervention: Fosravuconazole (100 mg orally once a day for 12 weeks)
Number of subjects: 0
Study: 28599665

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs capsules (1.8g EPA and 1.2g DHA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 42
Study: 25796419

Group type: EXPERIMENTAL
Intervention: Silver sucrose octasulfate nasal gel (Silsos gel®)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (carbopol and propylene glycol)
Number of subjects: 34
Study: 25022114

Group type: EXPERIMENTAL
Intervention: Combined therapy (acupuncture and auricle cutting)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Auricle cutting (sham-acupuncture and auricle cutting)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Acupuncture (acupuncture and sham auricle cutting)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (sham-acupuncture and sham auricle cutting)
Number of subjects: 56
Study: 23288261

Group type: EXPERIMENTAL
Intervention: Biofeedback (BF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 40
Study: 19957790

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) group
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sinus rhythm (SR) group
Number of subjects: 39
Study: 18322606

Group type: EXPERIMENTAL
Intervention: KGQG
Number of subjects: 57

Group type: COMPARATOR
Intervention: Routine medications
Number of subjects: 57
Study: 14699491

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil/lamivudine
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil
Number of subjects: 59

Group type: COMPARATOR
Intervention: Lamivudine
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil or adefovir dipivoxil/lamivudine
Number of subjects: 59
Study: 12219889

Group type: EXPERIMENTAL
Intervention: Visual discrimination task with retention intervals of 50 msec to 800 msec
Number of subjects: 0
Study: 9822002

Group type: EXPERIMENTAL
Intervention: Ability to generate an airway pressure of 20 cm water
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ability to ventilate manually
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Black line on the LMA in midline
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Anterior movement of the larynx
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Outward movement of the LMA on inflation of the cuff
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Movements of the reservoir bag with spontaneous breathing
Number of subjects: 150

Group type: COMPARATOR
Intervention: Presence of resistance at the end of insertion
Number of subjects: 150

Group type: COMPARATOR
Intervention: Inability to advance LMA after inflation of the cuff
Number of subjects: 150

Group type: COMPARATOR
Intervention: Presence of a capnographic trace
Number of subjects: 150
Study: 10580682

Group type: EXPERIMENTAL
Intervention: Oral nifedipine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Intravenous magnesium sulfate
Number of subjects: 74
Study: 1669241

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 5000
Study: 6839797

Group type: EXPERIMENTAL
Intervention: 200 mg sulindac twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: 400 mg ibuprofen 3-times daily
Number of subjects: 30
Study: 29253915

Group type: EXPERIMENTAL
Intervention: Health programme (Intervention Group)
Number of subjects: 552

Group type: COMPARATOR
Intervention: Survey (Control Group)
Number of subjects: 552
Study: 29937258

Group type: EXPERIMENTAL
Intervention: Child Life and Attention Skills (CLAS)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Parent-focused treatment (PFT)
Number of subjects: 199
Study: 27180620

Group type: EXPERIMENTAL
Intervention: PVI + box lesion
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: PVI + box lesion + LAA excision
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 176
Study: 24480619

Group type: EXPERIMENTAL
Intervention: Covered Stents (CS)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Bare Stents (BS)
Number of subjects: 129
Study: 22101443

Group type: EXPERIMENTAL
Intervention: Critical care (CCU)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Surgical ward care
Number of subjects: 153

Group type: COMPARATOR
Intervention: Ward care (for patients with anaerobic threshold >= 11 ml oxygen per kg per min)
Number of subjects: 153
Study: 20696797

Group type: EXPERIMENTAL
Intervention: Quality Initiative in Rectal Cancer strategy
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Normal practice (control)
Number of subjects: 1015
Study: 18269144

Group type: EXPERIMENTAL
Intervention: Moria M2 microkeratome
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: SCHWIND Carriazo‐Pendular microkeratome
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: IntraLase femtosecond laser
Number of subjects: 33
Study: 16432641

Group type: EXPERIMENTAL
Intervention: Chipped ice in a plastic bag (cold group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Room temperature water in a plastic bag (control group)
Number of subjects: 40
Study: 14555886

Group type: EXPERIMENTAL
Intervention: Beta-blocker bisoprolol (5 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10759937

Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study: 9307933

Group type: EXPERIMENTAL
Intervention: 3.8 g highly purified EPA
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 3.6 g DHA
Number of subjects: 58

Group type: COMPARATOR
Intervention: corn oil
Number of subjects: 58
Study: 8165609

Group type: EXPERIMENTAL
Intervention: Bay u3405 (thromboxane A2 receptor antagonist)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bay u3405
Number of subjects: 12
Study: 3532011

Group type: EXPERIMENTAL
Intervention: Budesonide 200 micrograms twice daily via pear spacer (PS)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Budesonide 200 micrograms twice daily directly from metered dose inhaler
Number of subjects: 25
Study: 30920878

Group type: EXPERIMENTAL
Intervention: Prophylactic radiotherapy (21 Gy in three fractions over three consecutive working days)
Number of subjects: 375

Group type: COMPARATOR
Intervention: No prophylactic radiotherapy
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Prophylactic radiotherapy
Number of subjects: 375
Study: 27632019

Group type: COMPARATOR
Intervention: Low-fat/high-sucrose (SUCR) meal
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SFA meal
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ghrelin
Number of subjects: 30
Study: 27654255

Group type: EXPERIMENTAL
Intervention: Vintafolide (2.5 mg intravenously, 3 times per week, weeks 1 and 3, every 28 days) + Pegylated Liposomal Doxorubicin (50 mg/m intravenously, day 1, every 28 days)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Pegylated Liposomal Doxorubicin alone (50 mg/m intravenously, day 1, every 28 days)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Combination therapy (Vintafolide + PLD)
Number of subjects: 94

Group type: COMPARATOR
Intervention: PLD alone
Number of subjects: 94
Study: 24001457

Group type: EXPERIMENTAL
Intervention: Trait Positive Arousal
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Trait Negative Arousal
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Left NAcc activity during anticipation of large gains (+$5.00)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Right anterior insula activity during anticipation of large losses (‐$5.00)
Number of subjects: 52
Study: 22214657

Group type: EXPERIMENTAL
Intervention: Distribution of evidence-based guideline for osteoporosis prevention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no guideline provided)
Number of subjects: 100
Study: 19935406

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid at doses of 15, 30, and 50 mg/kg per day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 18
Study: 17931082

Group type: EXPERIMENTAL
Intervention: Alikal Dolor (effervescent powder containing paracetamol 500 mg/sodium bicarbonate 2318 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Parageniol (paracetamol 500 mg coated tablets)
Number of subjects: 18